K-V Pharmaceutical (KV.A) filed for bankruptcy protection yesterday, citing the FDA's failure to enforce orphan drug marketing exclusivity for the Missouri firm's Makena drug for helping prevent premature births. This included enabling some state Medicaid agencies to limit access to the treatment. K-V also blamed manufacturing and marketing restrictions on some of its other products. (PR)